← Reviews
Open accessFull analysisNov 14, 2026

Fecal microbiota transplantation and peri-stoma microbiome management: narrative review of mechanisms and clinical translation

This narrative review proposes an unvalidated conceptual model (PSMM) for microbiome management in intestinal stoma patients; available clinical data are insufficient to support any definitive therapeutic recommendation.

Evidence levelDNarrative / animal / in vitro / mechanistic
Study typenarrative_review
Sample—
Effect directionInsufficient
CertaintyVery low
Clinical applicabilityVery low
Overinterpretation risk1/5 · Low
PICO
PopulationAdult patients with intestinal stoma (ileostomy or colostomy), temporary or permanent, undergoing surgery for colorectal cancer, IBD, diverticulitis, or trauma
InterventionFMT via efferent limb of stoma, defined microbial consortia, bacteriophage therapy, or perioperative dietary prehabilitation strategies
ComparatorNo intervention, standard of care, or historical controls (most cited studies lack an adequate comparator)
OutcomeClinical response of FMT in diversion colitis; Anastomotic leakage after stoma reversal; Butyrate concentration in ileostomy effluent; Prevalence of diversion colitis in stoma patients; Phage therapy decolonization for E. faecalis pre-reversal; Metabolic complications in permanent stoma carriers; High-output ileostomy (>1500 mL/24h)

Summary of findings

OutcomeEffect95% CICertaintyClinical relevanceNotes
Clinical response of FMT in diversion colitisresponse rate ~70%, in the IC 95%, in the comparator, case series only—Very low—2 studies
Anastomotic leakage after stoma reversalno effect size, in the IC 95%, small trials with severe methodological limitations—Very low—2 studies
Butyrate concentration in ileostomy effluent5-10% of normal fecal butyrate levels, observational, in the IC 95%—Very low—1 studies
Prevalence of diversion colitis in stoma patients30-60% prevalence, observational aggregate, in the IC 95%—Low—
Phage therapy decolonization for E. faecalis pre-reversalpreclinical rodent models only, in the human data—Very low—
Metabolic complications in permanent stoma carriersindirect associative data only, in the effect size, in the IC 95%—Very low—
High-output ileostomy (>1500 mL/24h)10-16% incidence reported, in the microbiome intervention data, in the effect size—Very low—

Context

Intestinal stomas affect 300,000–500,000 patients per year worldwide, with diversion colitis occurring in 30–60% and high-output ileostomy in 10–16% of cases. Dysbiosis associated with fecal stream diversion is mechanistically plausible as a therapeutic target, but controlled clinical evidence is scarce. No prior systematic review integrated microbiome management across the full stoma lifecycle.

What the study showed

FMT administered via the efferent limb of the stoma in small, uncontrolled case series showed clinical response rates of approximately 70% for diversion colitis, without reported 95% CI. Preliminary data suggest reduced anastomotic leakage with pre-reversal FMT, but these derive from trials with severe methodological limitations and no absolute numbers or effect sizes reported. Butyrate in ileostomy effluent reaches only 5–10% of normal fecal levels (observational, no CI). No primary clinical outcome was evaluated in an adequately powered RCT.

How it was done

Non-systematic narrative review. Authors synthesize data from observational studies, case series, experimental models (rodents), and mechanistic in vitro/ex vivo studies. No registered protocol, no explicit search strategy, no formal risk-of-bias assessment (AMSTAR-2 not applicable given absence of systematic methodology). The PSMM framework is an author-proposed conceptual model, not derived from meta-analysis or systematic review.

Effect magnitude

No effect size with 95% CI is reported for any clinical outcome. The 70% response rate for FMT in diversion colitis derives from case series without a comparator group.

Risk of bias

Narrative review without systematic methodology (no PRISMA, AMSTAR-2 not applicable); absence of data from adequately powered RCTs for any described intervention; publication bias favoring positive results in case series; PSMM model proposed by the authors themselves without prospective validation; extrapolation from preclinical data (rodents) to human practice without established empirical basis.

Interpretation limit

What this study does NOT prove

This study does not prove clinical efficacy of FMT or any other microbiome intervention in stoma patients. It does not establish causality between dysbiosis and anastomotic leakage in humans, nor does it validate the PSMM model in any clinical population.

In clinical practice

None of the described interventions has sufficient evidence for routine clinical adoption. Clinicians should recognize diversion colitis as a real condition affecting 30–60% of stoma patients and maintain clinical vigilance. FMT for diversion colitis should be considered only in the context of a controlled clinical trial, not as standard practice.

Limitations

Narrative review without systematic methodology (no PRISMA, AMSTAR-2 not applicable); absence of data from adequately powered RCTs for any described intervention; publication bias favoring positive results in case series; PSMM model proposed by the authors themselves without prospective validation; extrapolation from preclinical data (rodents) to human practice without established empirical basis.

What is still missing

Adequately powered RCTs evaluating FMT versus standard care in patients with symptomatic diversion colitis, and prospective cohort studies evaluating the association between pre-reversal dysbiosis and anastomotic leakage with rigorously defined clinical endpoints.

Technical appendix

Version history

  • 1.0 · 2026-11-14 — Auto-generated under Evidence Standard v1.0

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.